Результаты поиска

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one : National Harbor, MD, USA. 9-13 November 2016

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Multimodal Treatment of Bone Metastasis-A Surgical Perspective.

Over the past decades there has been an increase in the incidence of cancer worldwide. With the advancement in treatment, patient survival has improved in tandem with the increasing incidence. This, together with the availability of advanced modern diagnostic modalities, has resulted in more cases of metastatic bone disease being identified. Bone metastasis is an ongoing problem and has significant morbidity implications for patients affected. Multimodal treatment strategies are required in dealing with metastatic bone disease, which include both surgical and non-surgical treatment options. In

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma.

Renal impairment (RI) is a serious complication in multiple myeloma (MM), linked to poor survival and early mortality. Rapid renal recovery improves outcomes, yet patients with RI have been excluded from most key trials in transplant-eligible newly diagnosed (TE-ND) MM. REMNANT is an ongoing, academic, multicenter phase 2/3 study in TE-NDMM patients aged 18-75, regardless of baseline renal function. Here, we report a subanalysis of the non-randomized phase 2 component. All patients received four 21-day cycles of induction with bortezomib, lenalidomide, and dexamethasone. Lenalidomide was dosed

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives.

Advancements in the field of cellular immunotherapy have accelerated in recent years and have changed the treatment landscape for a variety of hematologic malignancies. Cellular immunotherapy strategies exploit the patient's immune system to kill cancer cells. The successful use of CD19 chimeric antigen receptor (CAR) T-cells in treating B-cell malignancies is the paradigm of this revolution, and numerous ongoing studies are investigating and extending this approach to other malignancies. However, resistance to CAR-T-cell therapy and non-durable efficacy have prevented CAR-T-cells from becomin

Совпадение в полном тексте источника
… Another phase I study has reported that multiple doses of NK cells (days −2, +7, and +28), which were expanded ex vivo with K562-mbIL21-41BBL feeder cells, can effectively prevent leukemia relapse 59 . …

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

The fourth "Melanoma Bridge Meeting" took place in Naples, December 5 to 8th, 2013. The four topics discussed at this meeting were: Diagnosis and New Procedures, Molecular Advances and Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers.

Совпадение в полном тексте источника
… TILs are re-infused after isolation from fresh tumor specimens, enrichment and expansion with IL-2 plus anti-CD3 antibody in the presence of feeder cells. Pretreatment leukocyte depletion enhances TILs therapy clinical outcomes. …

From lab to lifesaver: the rise of CAR T-cell therapy in oncology.

BackgroundRecently, cancer treatment paradigms have shifted dramatically with the advent of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapy. Despite it is revolutionary positive outcomes in treating hematologic malignancies, challenges such as severe toxicities, high treatment costs, and limited efficacy in solid tumors persist. This review highlights these limitations and the ongoing need for innovation in CAR T-cell therapy.Main bodyThis manuscript provides a comprehensive review of most current advancements in CAR T-cell therapy, with a focus on targeting its im

Совпадение в полном тексте источника
… Feeder cells can significantly boost NK proliferation; nevertheless, they might be challenging to remove entirely from the culture, raising safety concerns [ 8 ]. …

The therapeutic role of γδT cells in TNBC.

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that presents significant therapeutic challenges due to the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. As a result, conventional hormonal and targeted therapies are largely ineffective, underscoring the urgent need for novel treatment strategies. γδT cells, known for their robust anti-tumor properties, show considerable potential in TNBC treatment as they can identify and eliminate tumor cells without reliance on MHC restrictions. These cells de

Совпадение в полном тексте источника
… Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells . …

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in personalized medicine. In this strategy, a patient's own T lymphocytes are genetically reprogrammed to encode a synthetic receptor that binds a tumor antigen, allowing T cells to recognize and kill antigen-expressing cancer cells. As a result of complete and durable responses in individuals who are refractory to standard of care therapy, CAR T cells directed against the CD19 protein have been granted United States Food and Drug Administration (FDA) approval as a therapy for treatment of pediatric and young adult acu

Совпадение в полном тексте источника
… Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol. (1997) 159:5921–30. 31. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. …

Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer.

Cancer immunotherapy has emerged as a transformative approach in oncology, offering alternatives beyond traditional treatments. This narrative review focuses on major innovations, including adoptive cell therapy (ACT), chimeric antigen receptor T-cells (CAR-T), T-cell receptor (TCR) engineering, monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs). The central aim of this article is to analyze how these technologies improve antitumor responses and help overcome resistance in hematologic and solid tumors. This narrative review combines the latest

Совпадение в полном тексте источника
… In recent years, significant advances in cellular immunotherapy have included the use of stimulating or feeder cells to expand effective immune cells such as NK cells and TILs, along with the development of engineered T-cell receptors (TCRs) and CAR T-cells, which are frequently employed in adoptive …

Osteoprotective Roles of Green Tea Catechins.

Osteoporosis is the second most common disease only secondary to cardiovascular disease, with the risk of fracture increasing with age. Osteoporosis is caused by an imbalance between osteoblastogenesis and osteoclastogenesis processes. Osteoclastogenesis may be enhanced, osteoblastogenesis may be reduced, or both may be evident. Inflammation and high reactive oxygen enhance osteoclastogenesis while reducing osteoblastogenesis by inducing osteoblast apoptosis and suppressing osteoblastic proliferation and differentiation. Catechins, the main polyphenols found in green tea with potent anti-oxida

Methods of Topical Administration of Drugs and Biological Active Substances for Dental Implants-A Narrative Review.

Dental implants are, nowadays, established surgical devices for the restoration of lost teeth. Considered as an alternative for traditional prosthetic appliances, dental implants surpass them in reliability and patient feedback. Local drug delivery around the implants promotes osseointegration and reduces peri-implantitis. However, there are currently no methods of a multiple, precise topical administration of drugs to the implant area. Engineering coatings on the implants, drug application on carriers during implantation, or gingival pockets do not meet all requirements of dental surgeons. Th

Prospects for γδ T cells and chimeric antigen receptor γδ T cells in cancer immunotherapy.

γδ T cells, a type of specialized T cell, differ from alpha-beta T cells due to the presence of γ and δ chain surface T cell receptors. These receptors allow them to directly recognize and bind antigenic molecules without the requirement of attachment to MHC or APC antigen presentation. Given their intrinsic properties and functional versatility, γδ T cells are under intensive investigation as carriers for chimeric antigen receptor (CAR) in the context of cancer therapy. In this regard, γδ CAR-T cells have demonstrated great potential to overcome the limitations of antigen recognition with the

Совпадение в полном тексте источника
… Large-scale expansion of Vγ9vδ2 T cells with engineered K562 feeder cells in G-rex vessels and their use as chimeric antigen receptor-modified effector cells. Cytotherapy. (2018) 20:420–35. doi: 10.1016/j.jcyt.2017.12.014 108. Boucher JC, Yu B, Li G, Shrestha B, Sallman D, Landin AM, et al. …

Клинические 7 Тесла магнитный резонансный снимок: воздействие и ценность пациента в неврологических расстройствах.

Магнитный резонансный снимок (MRI) является краеугольным камнем неинвазивной диагностики и контроля за лечением, особенно в случае заболеваний центральной нервной системы. Хотя 1.5- и 3 Тесла (Т) сильные стороны поля остаются клиническим стандартом, появление 7 МРТ представляет собой преобразующий шаг вперед, предлагающий высокое пространственное разрешение, контраст и чувствительность для визуализации нейроанатомии, метаболизма и функции. Последние нововведения, включая параллельную передачу и глубокую реконструкцию на основе накопленного опыта, позволили решить многие ранее возникшие техниче

The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies.

IntroductionImmunotherapy has revolutionized how cancer is treated. Many of these immunotherapies rely on ex vivo expansion of immune cells, classically T cells. Still, several immunological obstacles remain, including tumor impermeability by immune cells and the immunosuppressive nature of the tumor microenvironment (TME). Logistically, high costs of treatment and variable clinical responses have also plagued traditional T cell-based immunotherapies.MethodsTo review the existing literature on cellular immunotherapy, the PubMed database was searched for publications using variations of the phr

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advance

Совпадение в полном тексте источника
… Retroviral Gene Transfer Into Primary Human NK Cells Activated by IL-2 and K562 Feeder Cells Expressing Membrane-Bound IL-21. J Immunol Methods (2017) 450:90–4. doi: 10.1016/j.jim.2017.08.003 92. Watanabe K, Nishikawa H. …

Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

The plasma cell proliferative disorders monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple myeloma (MM) are characterized by an accumulation of transformed clonal plasma cells in the bone marrow and production of monoclonal immunoglobulin. They typically affect an older population, with median age of diagnosis of approximately 70 years. In both disorders, there is an increased risk of infection due to the immunosuppressive effects of disease and conjointly of therapy in MM, and response to vaccination to counter infection is compromised. The underlying factors in

The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle?

Natural killer (NK) cells are innate lymphocytes that play an important role in immunosurveillance, acting alongside other immune cells in the response against various types of malignant tumors and the prevention of metastasis. Since their discovery in the 1970s, they have been thoroughly studied for their capacity to kill neoplastic cells without the need for previous sensitization, executing rapid and robust cytotoxic activity, but also helper functions. In agreement with this, NK cells are being exploited in many ways to treat cancer. The broad arsenal of NK-based therapies includes adoptiv

Совпадение в полном тексте источника
… This can be achieved by the use of cytokines such as IL-2 or IL-15, or through combinations of IL-12, IL-15, and IL-18; activating antibodies (such as OKT3) or “feeder” cells, such as K-562 cells, can also have this effect [ 156 ]. … In this case, the patients’ PBMCs were stimulated with the combination of irradiated feeder cells (HFWT) and IL-2 [ 184 ], leading to a selective expansion of the NK cells (median 85.9% purity). …

The Black Hole: CAR T Cell Therapy in AML.

Despite exhaustive studies, researchers have made little progress in the field of adoptive cellular therapies for relapsed/refractory acute myeloid leukemia (AML), unlike the notable uptake for B cell malignancies. Various single antigen-targeting chimeric antigen receptor (CAR) T cell Phase I trials have been established worldwide and have recruited approximately 100 patients. The high heterogeneity at the genetic and molecular levels within and between AML patients resembles a black hole: a great gravitational field that sucks in everything. One must consider the fact that only around 30% of

Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024.

The rising global cancer burden underscores the urgent need for innovative and effective therapies. Molecular and cellular immunology advances have revolutionized cancer immunotherapy, transforming laboratory discoveries into clinical breakthroughs. The Second Bone Marrow Transplant and Cellular Therapy Congress, held in Abu Dhabi, United Arab Emirates (UAE), on October 26th - 27th, 2024, and sponsored by the Abu Dhabi Stem Cells Center (ADSCC), convened global experts to discuss cutting-edge developments in adoptive cell transfer (ACT); chimeric antigen receptor T-cell (CAR-T) therapy, tumor-

Совпадение в полном тексте источника
… Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia. Front Immunol. (2024) 15:1415328. doi: 10.3389/fimmu.2024.1415328, PMID: 67. …

The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.

PurposeLymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases.MethodsThis comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T c

Совпадение в полном тексте источника
… While IL-2, feeder cells, and anti-CD3 antibodies have been used for years, the activation and proliferation of T cells outside the body are less efficient compared to the use of beads coated with anti-CD3/anti-CD28 monoclonal antibodies or cell-based artificial antigen-presenting cells (aAPC). 83 Magnetic …